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Background: Approximately 30 % of all breast cancer is at least partly attributed to hereditary factors. Familial
breast cancer is often inherited in the context of cancer syndromes. The most commonly mutated genes are BRCA1
and BRCA2 in hereditary breast and ovarian cancer syndrome. The genetic background in families with hereditary
breast cancer without predisposing germ line mutations in BRCA1 and BRCA2 (non-BRCA families) is still to a large
extent unclear even though progress has been made. The aim of this study was to compare cancer proportions in
familial non-BRCA hereditary breast cancer compared to the general population in search of putative new breast
cancer syndromes.
Methods: Pedigrees from 334 non-BRCA hereditary breast cancer families in the county of Stockholm, Sweden,
were investigated and the distribution of cancer diagnoses other than breast cancer was compared with the
distribution of cancer diagnoses in the general Swedish population in two reference years, 1970 and 2010.
A cancer diagnosis was regarded as overrepresented in the non-BRCA families if the confidence interval was
above both population reference values.
Results: We found that endometrial cancer was overrepresented in the non-BRCA families with a 6.36 % proportion
(CI 4.67–8.2) compared to the proportion in the general population in the reference years 1970 (3.07 %) and 2010
(2.64 %). Moreover tumours of the ovary, liver, pancreas and prostate were overrepresented.
Conclusion: In conclusion, we found an overrepresentation of endometrial cancer in our cohort of hereditary
non-BRCA families. Our result supports previous inconsistent reports of a putative breast and endometrial cancer
syndrome. An association has been suggested in studies of families with several cases of breast cancer in close
relatives or bilateral breast cancer. To clarify this issue we suggest further studies on a breast and endometrial
cancer syndrome in cohorts with a strong pattern of hereditary breast cancer. Identifying new breast cancer
syndromes is of importance to improve genetic counselling for women at risk and a first step towards detection
of new susceptibility genes.
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Although breast cancer is the most common form of
cancer in women, the incidence varies greatly, being
highest in developed countries, but also increasing in de-
veloping nations. The standardised incidence in Western
Europe is as high as 90 per 100,000 and approximately* Correspondence: camilla.wendt@karolinska.se
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disease [1, 2].
Identified risk factors include use of exogenous hor-
mones, reproductive factors and obesity though a family
history of breast cancer is the most important one. The
risk increases with the number of close relatives affected,
especially if they are young at the time of diagnosis. The
age of onset in these families is lower than in the case of
sporadic breast cancer [3, 4]. Depending on the number
of affected relatives and the age at onset, the conferred
risk ranges from almost doubled to fivefold compared to
the 10 % population risk [3]. A Scandinavian twin studyrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Swedish Breast Cancer Group BRCA 1 and BRCA 2
screening criteria
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cancers [5].
Major advances in the understanding of breast cancer
susceptibility were made in the 1990s when the two major
high-risk breast cancer and ovarian cancer predisposition
genes BRCA1 and BRCA2 were identified [6–8]. Signifi-
cant for all identified high-risk breast cancer predispos-
ition genes is that they are observed in the context of
breast cancer syndromes involving not only breast cancer
but also an increased risk of other tumour types. Apart
from the Hereditary Breast and Ovarian Cancer Syndrome
caused by mutations in BRCA1 and BRCA2, these include
Li-Fraumeni Syndrome (TP53) [9], Cowden Syndrome
(PTEN) [10], Peutz-Jeghers Syndrome (STK11) [11, 12]
and Hereditary Diffuse Gastric and Lobular Breast Cancer
Syndrome (CDH1) [13]. In addition, most of the identified
moderate penetrance breast cancer genes also predispose
to other tumour types. Besides an intermediate increased
risk of breast cancer, CHEK2 mutations have been associ-
ated with an increased risk of bladder, colorectal, prostate
and kidney cancer [14–16]. Mutations in BRIP1 have been
associated with increased risk of breast and ovarian cancer
[17, 18]. Carriers of deleterious PALB2 mutations have a
moderate to high risk of breast cancer and also an
increased risk of pancreatic cancer and ovarian cancer
[19–21]. Inherited deleterious ATM mutations have been
associated with both breast cancer and pancreatic cancer
predisposition [22, 23]. These moderate risk genes confer
a 2–4 fold risk compared to the 10 % risk in the general
population. In recent years genome-wide association
studies in large cohorts have identified multiple low risk
variants that each confer a modest risk though the com-
bined effect can be substantial [24].
Although deleterious BRCA1 and BRCA2 mutations
constitute the most common breast cancer syndrome,
they explain the genetic background in only 1–3 % in
sporadic breast cancer populations and about 15 % of
familial breast cancer [25–27]. Altogether, BRCA1,
BRCA2 and the other less common high-risk genes are
estimated to account for not more than 20 % of the
familial risk [28, 29]. Since moderate risk genes are
estimated to account for approximately 5 % and low risk
genes for another 14 % of familial breast cancer risk, the
genetic background in familial breast cancer still remains
unclear to a large extent [24, 30].
In summary, these findings suggest that there may be
other breast cancer syndromes yet to be identified. This
is supported by a Swedish study from 2007, by von
Wachenfeldt et al., who investigated tumour spectrum
in 803 Swedish families with hereditary breast cancer
suggesting that breast cancer and endometrial cancer
could constitute a new syndrome [31]. The Department
of Clinical Genetics at Karolinska University Hospital
has a long history of genetic counselling in breast cancerfamilies in the Stockholm County. In all families fulfill-
ing national screening criteria, pathogenic mutations in
BRCA1 and 2 are ruled out (Fig. 1). Other previously
identified risk genes are analysed only if family pattern
indicates a specific syndrome. Accordingly, we now have
a large cohort of consecutive families with hereditary
breast cancer where the underlying cause is unclear. Our
aim in this study was to search for new breast cancer
syndromes in that cohort of non-BRCA families. We
were particularly interested in carrying out a follow up
on the results of a putative breast and endometrial can-
cer syndrome.
Methods
All families with hereditary breast cancer who were sub-
jected to genetic screening of BRCA1 and BRCA2 from
February 2000 to January 2012 in the county of
Stockholm, Sweden, were eligible for the study. This time
period was chosen in order to avoid risking an overlap
with the von Wachenfeldt study [31]. Probands in these
families had either been referred or had contacted
Karolinska University Hospital themselves for genetic
counselling. Pedigrees were constructed for each family
and the genetic counsellor verified cancer diagnosis
through medical records, information from the Swedish
cancer registry and death certificates when possible and if
it was considered of importance in the individual family.
Families with disease causing variants in the breast cancer
genes BRCA1 or BRCA2 or other previously identified
cancer syndromes were excluded. All genetic testing was
performed in the same laboratory at the Department of
Oncology at Lund University Hospital. For BRCA muta-
tion analysis, denaturing high performance liquid chroma-
tography (DHPLC) was used as the screening tool
between 2000 and 2005. In addition to DHPLC, from
2006 to 2010 multiple ligation-dependent probe amplifica-
tion (MLPA) was performed to exclude larger genomic
rearrangements. Together, the DHPLC and MLPA have a
stated sensitivity of 95 %. For cases before 2006, blood
samples were reanalysed using MLPA when the technique
was introduced. For samples from the year 2010 and later,
analysis was performed using Next Generation Sequen-
cing with a sensitivity of over 95 %.
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and included if they contained at least two cases of breast
cancer and one case of any other type of cancer in first or
second degree relatives or first cousins on either maternal
or paternal branch of the family. Kinship was always re-
lated to the index patient. If these criteria were fulfilled in
both the maternal and the paternal branches, diagnoses
from both branches were registered, however, each indi-
vidual cancer diagnosis could only be included once
(Fig. 2). All diagnoses other than breast cancer in first or
second-degree relatives or cousins were registered as well
as age at onset when data was available.
Distribution of cancer diagnoses in the data was com-
pared to the distribution of cancer diagnoses in the
general Swedish population. Since selection of cases was
made on the basis of breast cancer diagnoses only, diagno-
ses other than breast cancer were used in the comparison.
Data of cancer diagnoses in the Swedish population was
obtained from the National Board of Health and Welfare
(Socialstyrelsen). Indirect standardisation was used here to
adjust the data from the Swedish population to that of the
relatives with cancer diagnoses with regard to gender and
age. Age was categorised into 5-year intervals. For rela-
tives with missing data on gender or age, the method data
Missing Completely At Random [32] was assumed.
Cancer cases in the relatives were assumed to be inde-
pendent of each other. Confidence intervals were
calculated separately for each cancer diagnosis, using aFig. 2 Maternal and paternal branches are considered as two families altho
with short lines and paternal branch marked with long linesbinomial distribution. The number of cases was then
transformed into proportion of cases by dividing by the
total number of observed cases. Population data were as-
sumed to reflect a true distribution, and were used as ref-
erence values. Two reference years were chosen, 1970 and
2010. A cancer diagnosis was regarded as overrepresented
in the relatives of the breast cancer patients if the confi-
dence interval was above both population reference
values. All statistical analyses were performed in R (R Core
Team, 2012). Data entry was performed in EpiData
(Lauritsen).
Results
Pedigrees from 334 non-BRCA families remained for
inclusion in this study after excluding BRCA positive
families, families who did not fulfill inclusion criteria
and families with no pedigree available (Fig. 3). Within
these families we found 707 cases of cancer other than
breast cancer, equaling 2.2 cases per family. 54 % of the
cancer diagnoses were verified histologically from the
Swedish cancer registry, medical records or death certifi-
cates. In 33 families, diagnoses were registered from
both maternal and paternal branches (Fig. 2).
The proportions of different cancer types in the study
families were compared to the proportion of cancer types
in the Swedish cancer population in 1970 and 2010; the
method used is described above in material and methods.
We found an increased incidence of endometrial cancerugh all diagnosis are registrered only once. Maternal branch marked
Fig. 3 Flowchart illustrating inclusion and exclusion of study families
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study families compared to the incidence in the general
population in the reference years 1970 and 2010 (3.07 %
in 1970, 2.64 % in 2010). Also liver cancer was observed in
a higher proportion than expected (2.12 %; CI 1.13–3.25,
0.28 % in 1970 and 0.13 % in 2010) (Table 1). Moreover,
several BRCA-related cancer types were overrepresented
in the study population: ovarian cancer in 10.33 % (CI
8.2–12.59, 4.51 % in 1970, 1.93 % in 2010), prostate cancer
in 14.57 % (CI 12.02–17.26, 6.98 % in 1970, 11.95 % in
2010) and pancreatic cancer in 4.67 % (CI 3.11–6.22,
2.79 % in 1970, 1.54 % in 2010). In contrast, low incidence
cancer types such as small intestine cancer, thyroid cancerand other endocrine cancers were present in a lower pro-
portion in the study families compared to the reference
population. Several rare cancer types like genital cancers
were not represented at all in the study population
(Table 1).
Discussion
The main finding of the present study is that endometrial
cancer was overrepresented in the study population of
families with hereditary non-BRCA breast cancer com-
pared to the reference population, supporting the earlier
findings of a putative breast cancer and endometrial can-
cer syndrome [31]. A strength of the study, compared to
Table 1 Proportion of different cancer types in non-BRCA families





Prostate 103 14.57 12.02 17.26 6.98 11.95 CI above reference
Ovary/Fallopian tube 73 10.33 8.2 12.59 4.51 1.93 CI above reference
Colon 47 6.65 4.81 8.49 7.75 7.21 No
Lung 45 6.36 4.67 8.2 5.5 5.53 No
Uterus 45 6.36 4.67 8.2 3.07 2.64 CI above reference
Malignant melanoma 35 4.95 3.39 6.65 4.28 9.04 No
Brain and nervous system 34 4.81 3.25 6.51 7.66 6.12 No
Pancreas 33 4.67 3.11 6.22 2.79 1.54 CI above reference
Uterine cervix 33 4.67 3.11 6.22 4.85 2.98 No
Stomach 28 3.96 2.55 5.52 6.51 1.49 No
Abdomen UNS 25 3.54 2.26 4.95 0 0 CI above reference
Urinary tract 24 3.39 2.12 4.81 3.59 3.72 No
Kidney 23 3.25 1.98 4.67 4.13 2.28 No
Leukemia 23 3.25 1.98 4.67 4.55 5.25 No
Rectum and anus 21 2.97 1.84 4.24 3.73 3.72 No
Lymphoma 21 2.97 1.84 4.24 5.75 6.28 CI below reference
Liver 15 2.12 1.13 3.25 0.28 0.13 CI above reference
Biliary tract 13 1.84 0.99 2.83 2.85 1.47 No
Skin 13 1.84 0.99 2.83 2.4 7.92 No
Oesophagus 9 1.27 0.57 2.12 0.76 0.59 No
Connective tissue 8 1.13 0.42 1.98 1.43 1.15 No
Multiple myeloma 8 1.13 0.42 1.98 1.13 1.05 No
Testis 6 0.85 0.28 1.56 1.52 3.27 No
Thyroid 5 0.71 0.14 1.41 1.97 2.72 CI below reference
Mouth 4 0.57 0.14 1.13 0.91 1.2 No
Endocrine 4 0.57 0.14 1.13 2.31 2.01 CI below reference
Lip 2 0.28 0 0.71 0.65 0.18 No
Salivary gland 2 0.28 0 0.71 0.54 0.47 No
Larynx 2 0.28 0 0.71 0.56 0.29 No
Unspecified 2 0.28 0 0.71 3.29 2.36 CI below reference
Small intestine 1 0.14 0 0.42 0.43 0.47 CI below reference
Tongue 0 0 0 0 0.22 0.45 CI below reference
Peritoneum 0 0 0 0 0.03 0.16 CI below reference
Middle ear 0 0 0 0 0.38 0.17 CI below reference
Mediastinum 0 0 0 0 0.01 0.07 CI below reference
Placenta 0 0 0 0 0.11 0.05 CI below reference
Female genital 0 0 0 0 0.53 0.42 CI below reference
Male genital 0 0 0 0 0.24 0.14 CI below reference
Eye 0 0 0 0 0.55 0.45 CI below reference
Skeleton 0 0 0 0 0.82 0.57 CI below reference
Polycytemia vera 0 0 0 0 0.37 0.26 CI below reference
Myelofibrosis 0 0 0 0 0.03 0.32 CI below reference
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BRCA1 and BRCA2 have been excluded through standar-
dised techniques in the index patient in all of the families.
Subsequently, the study cohort is more likely to harbour
other genetic risk factors. The methodology was otherwise
similar to that used in the previous study. A potential fa-
milial association between endometrial cancer and breast
cancer has been studied in other settings with differing re-
sults, though few of the studies are based on cohorts with
familial clustering of breast cancer. Lynch et al. identified
an excess of endometrial cancer in families with two or
more cases of breast cancer [33]. In families with a history
of endometrial cancer Andersson et al. found a signifi-
cantly increased risk for breast cancer in first-degree rela-
tives of women affected by bilateral breast cancer [34]. In
a prospective cohort study, Kazerouni et al. found no as-
sociation between familial breast cancer and endometrial
cancer. However the risk of endometrial cancer in women
with a first-degree relative with bilateral breast cancer was
increased by 40 % though that increase was not statisti-
cally significant [35]. Bilateral breast cancer and also the
number of cases and age at onset are markers of familial
breast cancer and this indicates that the elevated risk of
cancer is influenced by a genetic mechanism [36, 37].
Given these points, the results from Kazerouni et al.
and Andersson et al. are of great interest. Contrary to
this, Tzortzatos et al. found no association between
endometrial cancer in a study on tumour spectrum in a
cohort of consecutive cases of endometrial cancer and
breast cancer [38]. Pazzerini et al. investigated family
history of endometrial cancer in a case control cohort of
women with breast cancer and found no association
[39]. Regardless of family history, an association between
breast and endometrial cancer in the same individual,
double primaries, has been established in several studies
which provides evidence for an aetiological association
[35, 38]. The two tumour types also share hormonal and
reproductive risk factors such as obesity, nulliparity and
exogenous oestrogenes [40, 41]. Shared environmental
factors and/or genetic risk factors could be behind the
pathogenesis of theses cancers [40, 41]. Younger women
are especially at risk of developing serous carcinoma, a
subtype of endometrial cancer independent of oestrogen
and associated with risk of breast cancer, which raises
the possibility of predisposing genetic factors [42]. Two
autosomal dominant genetic disorders cause increased
risk of developing endometrial cancer. One of them,
Cowden syndrome, caused by germ-line mutations in
PTEN also confers increased risk of developing breast
cancer [10]. Hereditary non-polyposis colorectal cancer
(HNPCC) or Lynch syndrome is caused by a defective
mismatch repair system and causes increased risk of de-
veloping endometrial cancer. Evidence for an association
with breast cancer risk has not been shown even thoughsome role of mismatch repair genes in breast cancer de-
velopment in these families has been suggested [43, 44].
In our cohort, all pedigrees were assessed by genetic
counsellors and in relevant cases specific high risk
syndromes were ruled out by genetic screening. It is
therefore unlikely that families with either Cowden or
Lynch syndrome are included in the study. Tamoxifen
treatment is used in adjuvant breast cancer treatment
and has a carcinogenic effect on the endometrium in
postmenopausal women and doubles the risk of endomet-
rial cancer and the risk increases with longer duration
[45–47]. In our cohort, four women were affected by
endometrial cancer between 1 and 18 years after a breast
cancer diagnosis. One of these women with breast cancer
was diagnosed before Tamoxifen was introduced onto the
market. Two of the women were affected at a young age
in the 1980s; Tamoxifen was not used in premenopausal
women in Sweden at that time. Thereby, the development
of endometrial cancer subsequent to breast cancer cannot
be attributed to Tamoxifen use in these women. The
fourth case was a premenopausal woman who received
2 years of adjuvant Goserelin and Tamoxifen.
However, there are several issues that need to be
discussed. In general, the awareness of hereditary breast
and ovarian cancer syndrome is good among clinicians.
Therefore, there is a possibility that the large proportion
of ovarian cancer could be due to selection bias. Selec-
tion bias could also partly explain the excess of other
types of malignancies in the study group since having
any cancer diagnosis other than breast cancer might
result in a referral for genetic counselling. Nonetheless,
not all cancer types were overrepresented in the families.
One hundred fifty eight pedigrees could not be obtained
but it is unlikely that that would cause any kind of bias.
A random sample from medical records for the families
with missing pedigrees showed that most of these fam-
ilies did not fulfil inclusion criteria and that a pedigree
was not constructed due to only one affected woman at
a young age.
In the study, all diagnoses in first or second-degree rela-
tives or first cousins were included regardless of whether
they were verified through medical records, death certifi-
cates or not. We decided to include unverified diagnoses
so as not to lose potentially important information and
since the accuracy of information on family history of can-
cer in close relatives gathered from probands is generally
high [48, 49]. Nevertheless, in order to reduce the risk for
misclassifications of malignancies as well as over- or
underreporting due to recall bias, malignancies in third-
degree relatives were included only in first cousins and
not in older generations. Distinguishing ovarian cancers
from endometrial or cervical cancers is important in order
to correctly identify all families with hereditary breast and
ovarian cancer syndrome since they can be offered genetic
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ing cancer diagnoses histologically in families with a history
of gynaecological tumours and the majority of gynaeco-
logical cancers (e.g. 78 % of cases of endometrial cancer)
were verified through medical records or death certificates.
In contrast, malignancies such as lung cancer and liver
cancer were verified to a smaller degree and the over-
representation of liver cancer may partly be an effect of
misclassification of metastatic liver disease. As for rare
tumour types it is difficult to draw any conclusions since
the statistical method compares proportions not incidence
(a higher incidence in the study population may go un-
detected since proportions will be dominated by the most
common cancer types).
We also found an overrepresentation of prostate,
ovarian and pancreatic cancer. Germ line mutations of
BRCA2 are associated with not only an increased risk of
breast cancer and ovarian cancer but also with prostate
cancer and pancreatic cancer. The result therefore sug-
gests a BRCA2-like syndrome in non-BRCA families,
bearing in mind that most identified moderate risk
genes functionally interact with BRCA1 and BRCA2.
However, it has been considered unlikely that more risk
genes with effects similar to BRCA1 and BRCA2 exist.
Extensive search with linkage studies has failed to iden-
tify further high penetrance risk genes affecting breast
cancer susceptibility. Nevertheless, Antoniou et al. re-
cently presented data on breast cancer risk attributed to
PALB2 mutations at the same level as BRCA2 mutations
[19]. In addition, the risk was higher for PALB2 muta-
tion carriers with a family history of breast cancer com-
pared to no family history suggesting that the risk is
influenced by other genetic factors and/or environmen-
tal factors. The PALB2 protein interacts with BRCA2 in
homologous recombination and double strand break re-
pair. As with BRCA2, germ line mutations of PALB2
confer increased risk of breast cancer as well as ovarian
and pancreatic cancer [20, 21]. Since PALB2 mutations
are rare, the contribution to the increased risk for these
tumour types should be limited in the study cohort.
Nevertheless, PALB2 mutations and pathogenic muta-
tions in other genes involved in the same pathway as
BRCA2 could explain a minor part of the excess of pan-
creatic and ovarian cancer. It has also been suggested
that a polygenic model in which a large number of
moderate and/or low risk genes combined has multi-
plicative effects on risk and could partially explain the
genetic background in familial breast cancer [29]. Since
the sensitivity of BRCA mutation testing is 95 %, a part
of the excess of ovarian, pancreatic and prostate
cancers could reflect false negative screening in the
research cohort. As mentioned above, a part of at least
the excess of ovarian cancer could be a result of
selection bias.Conclusions
To summarise, we found an overrepresentation of
endometrial cancer in our cohort of hereditary non-
BRCA families, which supports earlier findings that
breast and endometrial cancer may constitute a breast
cancer syndrome. Since results from studies are diver-
gent this issue needs to be resolved by further studies
preferably on cohorts with two close relatives or more
affected by breast cancer or bilateral breast cancer. The
conflicting results could be due to methodology since
the association may only be evident in families with a
strong pattern of breast cancer susceptibility. Identify-
ing new breast cancer syndromes is of importance to
reach more women at increased risk of cancer with
preventive programmes. It is also a first step towards
detection of new susceptibility genes.
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